---
document_datetime: 2023-09-21 20:58:36
document_pages: 25
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zebinix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zebinix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 14.0713529
conversion_datetime: 2025-12-19 14:13:31.069352
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zebinix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1267/ 202104   | Periodic Safety Update EU Single assessment - eslicarbazepine acetate  | 16/12/2021                          | 04/03/2022                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1267/202104. |
| IB/0083              | B.II.d.z - Change in control of the Finished Product - Other variation | 08/02/2022                          | n/a                                         |                                  |                                                                                                                                           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0084   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   | 24/01/2022   | n/a   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0081   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                     | 20/01/2022   | n/a   |
| IA/0082   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                  | 05/01/2022   | n/a   |
| IA/0080   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   | 16/12/2021   | n/a   |
| IA/0079   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                     | 01/10/2021   | n/a   |
| IB/0078/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of                             | 18/08/2021   | n/a   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | the AS - Minor change in the manufacturing process of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0076 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/05/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| N/0075             | Update of the Package Leaflet with revised contact details of local representative for Belgium, Luxembourg, the Netherlands, Germany, Hungary, Austria, Czech Republic, France, Ireland, Slovakia, Italy, Denmark, Finland, Iceland, Norway, Sweden and UK. Additionally, the MAH took the opportunity to introduce minor editorial amendments to the local representative entry for Greece. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/01/2021 | 10/05/2021 | PL          |                                                                                                                                           |
| II/0074            | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                             | 17/04/2020 | 10/05/2021 | SmPC and PL |                                                                                                                                           |
| IAIN/0073/G        | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                        | 04/12/2019 | n/a        |             |                                                                                                                                           |
| PSUSA/1267/ 201810 | Periodic Safety Update EU Single assessment - eslicarbazepine acetate                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/06/2019 | 23/09/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1267/201810. |

<div style=\"page-break-after: always\"></div>

| IB/0072/G   | This was an application for a group of variations. B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation      | 20/06/2019   | n/a        |      |                                                                                                                                                                                                               |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0071     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                  | 10/05/2019   | n/a        |      |                                                                                                                                                                                                               |
| II/0069     | Update of section 4.2 of the SmPC in order to update information related to the switch of tablet and suspension formulation based on the final results from study IA-2093-132, a pharmacokinetic study conducted to address the post-approval commitment: to compare the pharmacokinetic profile of the oral suspension versus the tablets. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/03/2019   | 06/06/2019 | SmPC | The SmPC section 4.2 has been updated as follows: Based on comparative bioavailability data for the tablet and the suspension formulations, switching patients from one formulation to the other can be done. |
| II/0067     | Update of sections 4.8 and 5.1 of the SmPC in order to reflect the long-term safety and efficacy data obtained from the open-label extensions (parts II to                                                                                                                                                                                                                                                                                                    | 31/01/2019   | 06/06/2019 | SmPC | The SmPC section 4.8 and 5.1 have been updated as to include long-term safety data in the paediatric population obtained from open label extensions of the phase III study                                    |

<div style=\"page-break-after: always\"></div>

|           | V) of the phase III study BIA-2093-305. The study was assessed in procedure EMA/H/C/988/P46 025. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                       |            |            |             | and confirm that it was consistent with the known safety profile of the product with no new findings of concern.                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0068 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                           | 14/11/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0066   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/07/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0064   | Update of sections 4.4 and 4.8 of the SmPC to add information on urticaria, angioedema and severe cutaneous adverse reactions (SCARS) including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) as adverse drug reactions with unknown frequency, based on recent post-marketing safety data on Zebinix treatment. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 17/05/2018 | 06/06/2019 | SmPC and PL | Based on safety data from post-marketing sources (including spontaneous, health authority, and literature reports, respectively) and serious adverse events from interventional and non-interventional clinical trials, there is a causal association between urticaria, angioedema, severe cutaneous adverse reactions (SCARS) including Stevens- Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) and Zebinix. The Product information has been updated accordingly. |

<div style=\"page-break-after: always\"></div>

| IA/0065/G   | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   | 10/04/2018   | n/a        |                        |                                                         |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------|
| IB/0063/G   | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.6.z - Change(s) to therapeutic indication(s) -                                                                                                                                                     | 28/07/2017   | 18/09/2017 | SmPC, Labelling and PL |                                                         |
| II/0053     | Extension of indication for the tablet formulation to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/03/2017   | 28/04/2017 | SmPC, Annex            | For further information, please refer to the scientific |

<div style=\"page-break-after: always\"></div>

|           | include the use of Zebinix as monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy, in addition to the previously authorised indication as adjunctive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC have been updated. The Package Leaflet was updated in accordance. Furthermore, the product information is being brought in line with the latest QRD template version. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                   |            |     | II, Labelling and PL   | discussion Zebinix EMEA/H/C/000988/II/0053.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-----------------------------------------------|
| IB/0061/G | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation | 26/04/2017 | n/a |                        |                                               |

<div style=\"page-break-after: always\"></div>

| IB/0062/G   | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate   | 20/04/2017   | n/a        |                                  | from an already approved   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------|
| IB/0060     | B.II.f.1.a.2 - Stability of FP - Reduction of the shelf life of the finished product - After first opening                                                                                                                                                                                                                                                                                         | 13/02/2017   | 28/04/2017 | SmPC, Labelling and PL           |                            |
| IB/0059     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                          | 04/01/2017   | 28/04/2017 | SmPC                             |                            |
| II/0058     | B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions                                                                                                                                                                                       | 15/12/2016   | n/a        |                                  |                            |
|             | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                    | 13/10/2016   | 08/12/2016 | SmPC, Annex II, Labelling and PL | X/0050/G                   |

<div style=\"page-break-after: always\"></div>

| IA/0057            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 08/07/2016   | n/a   |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0056/G          | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its | 13/05/2016   | n/a   |                                   |
| PSUSA/1267/ 201510 | Periodic Safety Update EU Single assessment - eslicarbazepine acetate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/05/2016   | n/a   | PRAC Recommendation - maintenance |
| IA/0054/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 04/05/2016   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material   |            |            |             |                                                                                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0055            | B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/04/2016 | n/a        |             |                                                                                                                                                           |
| N/0052             | Update of the package leaflet with revised contact details of the local representative for Spain. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/04/2016 | 08/12/2016 | PL          |                                                                                                                                                           |
| PSUSA/1267/ 201410 | Periodic Safety Update EU Single assessment - eslicarbazepine acetate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/05/2015 | 28/07/2015 | SmPC and PL | Please refer to Zebinix PSUSA-1267-201410 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IAIN/0049/G        | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/07/2015 | n/a        |             |                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0048   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/04/2015 | n/a |
| IB/0047/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                                                              | 27/03/2015 | n/a |

<div style=\"page-break-after: always\"></div>

|         | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044 | Update of sections 4.2 and 5.1 of the SmPC with information from the concluded safety and efficacy study BIA-2093-401 in the elderly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                 | 25/09/2014 | 16/03/2015 | SmPC | The safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients were evaluated in one non-controlled study, with a duration of 26 weeks, in 72 elderly (aged â‰¥ 65 years). The data shows that the incidence of treatment emergent adverse events in this population (65.3 %) is similar to the general population enrolled in the double-blind epilepsy studies (66.8%).The most frequent individual treatment emergent adverse events were dizziness (12.5% of subjects), somnolence (9.7%), fatigue, convulsion and hyponatraemia (8.3%, each), nasopharyngitis (6.9%) and upper respiratory tract infection (5.6%). A total of 50 of the 72 subjects starting the study completed the 26-week treatment period that corresponds to a retention rate of 69.4%. No dose adjustment is needed in the elderly population |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       | provided that the renal function is not disturbed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041   | The MAH submitted the final report of study BIA- 2093-208 in children aged 6 to less than 16 years investigating the safety and efficacy of eslicarbazepine acetate in refractory partial onset seizures, including effect on cognitive function. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                    | 22/05/2014 | n/a        |                       | In this variation the company provided data from a recently completed study in children between 6-16 years of age with partial onset seizures refractory to treatment. The provided data did not change the product information of Zebinix.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0045   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                        | 21/05/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUV/0043 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/05/2014 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0035   | Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information based on the results from a newly completed phase III study in adult patients with refractory partial onset seizures as well as a an updated integrated safety analysis of available placebo-controlled clinical trials and other cumulative safety data. The Package Leaflet was updated accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/03/2014 | 16/03/2015 | SmPC, Annex II and PL | Following completion of the placebo-controlled part of a new study with Zebinix, an updated integrated analysis of all available placebo-controlled clinical safety data was performed. The review of these data in conjunction with cumulative safety information from open label studies, post-marketing reports and the known safety profile of other antiepileptic drugs of the same class resulted in the need to adjust the safety information. Several terms for adverse drug reactions were combined or deleted, frequencies were corrected and new terms were added. One new important potential risk of bone disorders was identified, which may be a class effect. Furthermore, one |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       | case of severe rash has been reported.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0042/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 29/01/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0040    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                            | 21/11/2013 | 22/01/2014 | SmPC, Annex II and PL | Based on the review of the cumulative quality, efficacy and safety data from clinical trials, post-marketing studies and spontaneous reports as well as the scientific literature, the CHMP concluded that there were no changes to the known benefits and safety concerns associated with Zebinix when used in the approved indication. The CHMP therefore concluded that the benefit/risk balance of Zebinix as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation remained favourable and recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0039   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                   | 02/07/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0037   | B.I.b.2.e - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                                                                                                     | 22/04/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|             | material/reagent/intermediate - Other to a test procedure (including replacement addition) for the AS or a starting                                                                                                                                                                                                                                                                                         |            |            |      | starting changes or material/intermediate   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------|
| IB/0036     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                   | 15/04/2013 | 22/01/2014 | SmPC |                                             |
| IA/0038/G   | application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 09/04/2013 | n/a        |      | This was an batch control/testing           |
| IB/0033     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                      | 30/11/2012 | n/a        |      |                                             |
| IAIN/0034/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                       | 16/11/2012 | n/a        |      |                                             |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032/G | This was an application for a group of variations. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                        | 14/11/2012 | 14/01/2013 | SmPC, Labelling and PL | C.I.3.a - Update of Section 4.4 of the SmPC to implement revised wording in relation to risk of hypersensitivity reactions potentially associated with HLA-A*3101 allele in Europeans and Japanese and recommendations on testing for HLA-B*1502 allele in some Asian populations as requested by the CHMP in July 2012. C.I.z - Update of Section 4.2 of the SmPC to implement dose recommendations for patients with renal insufficiency to use an optional initial dose of 200 mg once daily following the approval of the new 200mg tablet strength. |
| IB/0031/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 27/09/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| WS/0258   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Section 4.5 of the SmPC is updated in order to add information on the interaction with rosuvastatin. The Package Leaflet is updated accordingly. In addition, the list of local representatives in the Package Leaflet of Zebinix is updated. Furthermore, the PI is being brought in line with the latest QRD template version 8. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 21/06/2012   | 23/08/2012   | SmPC, Annex II, Labelling and PL   | This variation updated the Product Information of Exalief and Zebinix to reflect data from a clinical study which showed that concomitant treatment with rosuvastatin and eslicarbacepine acetate reduces rosuvastatin plasma concentration and available amount.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0024    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/06/2012   | 23/08/2012   | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                     |
| IB/0030   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                | 20/06/2012   | 23/08/2012   | SmPC                               | Implementation of agreed wording in sections 5.3 and 6.6 of the SmPC following the assessment of FU2 001.3 in order to inform about the environmental risk of eslicarbazepine acetate as well as provide advice on disposal.                                        |
| IB/0029/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where                                                                                                                                                                                                                                                                                                                                                                               | 21/05/2012   | n/a          |                                    |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | batch control/testing takes place B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                        | 10/02/2012 | 23/08/2012 | SmPC        |                                                                                                                                                                                                                                                                                                                                                          |
| WS/0120 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To add an alternative manufacturer of the active substance (eslicarbazepine acetate). B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions | 15/12/2011 | 15/12/2011 |             |                                                                                                                                                                                                                                                                                                                                                          |
| WS/0162 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SPC to add a number of adverse reactions resulting from CHMP assessment of an additional pooled analysis of phase III data. The PL has been updated accordingly. In addition, a                                                                                       | 22/09/2011 | 10/11/2011 | SmPC and PL | After CHMP assessment of the results obtained on an additional pooled analysis of the phase III data for eslicarbazepine acetate, the MAH has submitted a type II variation to add the adverse events 'irritability', 'chest pain' and 'urinary tract infection' to section 4.8 of the SPC as 'uncommon' events under the respective System Organ Class. |

<div style=\"page-break-after: always\"></div>

|           | cross-reference has been corrected in section 4.6 of the SmPC, and the contact details for the local representative in The Netherlands have been updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                       |            |     |          |                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|-------------------|
| IA/0023/G | an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already manufacturer | 27/10/2011 | n/a |          | This was approved |
|           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                | 18/10/2011 | n/a |          | IA/0022/G         |
| IA/0021/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                     | 13/04/2011 | n/a | Annex II |                   |

<div style=\"page-break-after: always\"></div>

|           | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018/G | This was an application for a group of variations. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/10/2010 | 29/11/2010 | SmPC and PL | Eslicarbazepine acetate is an antiepileptic drug which is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. At the time of the approval, the CHMP requested the MAH to investigate the possible drug-drug interaction with carbamazepine as a follow-up measure. In addition, the CHMP requested the investigation of the inducing effect of eslicarbazepine acetate on CYP3A4 in humans as a follow- up measure. In a drug-drug interaction study with carbamazepine, it was shown that concomitant administration of eslicarbazepine acetate 800 mg once daily and carbamazepine 400 mg twice daily resulted in an average decrease of approximately 30% in exposure to the active metabolite eslicarbazepine most likely caused by an increase in metabolism. The dose of eslicarbazepine acetate may therefore need to be increased when used concomitantly with carbamazepine. Concomitant intake of eslicarbazepine acetate did not alter the pharmacokinetic profile of carbamazepine or its metabolite carbamazepine- epoxide. A study to examine the induction of CYP3A4 by |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | eslicarbazepine acetate showed an average decrease of approximately 50 % in systemic exposure to simvastatin when co-administered with eslicarbazepine acetate 800 mg once daily. An increase of the simvastatin dose may therefore be required when used concomitantly with eslicarbazepine acetate. Section 4.5 of the SPC and section 2 of the PL have been updated with the new information, and the PI has been revised according to the current QRD template.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0020/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 26/11/2010 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |     |      | B.II.d.2.a - Change   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------|
| IB/0019 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                 | 28/10/2010 | n/a | SmPC |                       |
| N/0017  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                          | 18/12/2009 | n/a | PL   |                       |
| IB/0016 | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/10/2009 | n/a |      |                       |
| IA/0015 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                        | 29/09/2009 | n/a |      |                       |
| IB/0007 | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                                                                                                                                                                              | 05/06/2009 | n/a |      |                       |
| IB/0006 | IB_14_a_Change in manuf. of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/06/2009 | n/a |      |                       |

<div style=\"page-break-after: always\"></div>

|         | without Ph. Eur. certificate - change in manuf. site                                                                                                             |            |     |                 |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| IB/0005 | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                | 05/06/2009 | n/a |                 |
| IB/0004 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                         | 05/06/2009 | n/a |                 |
| IB/0003 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                         | 05/06/2009 | n/a |                 |
| IA/0014 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 18/05/2009 | n/a |                 |
| IA/0013 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                 | 18/05/2009 | n/a | Annex II and PL |
| IA/0012 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                   | 18/05/2009 | n/a |                 |
| IA/0011 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                   | 18/05/2009 | n/a |                 |
| IA/0010 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                   | 18/05/2009 | n/a |                 |
| IA/0009 | IA_32_b_Change in batch size of the finished product - downscaling down to 10-fold                                                                               | 18/05/2009 | n/a |                 |

<div style=\"page-break-after: always\"></div>

| IA/0008   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure   | 18/05/2009   | n/a   |              |
|-----------|--------------------------------------------------------------------------------------------------|--------------|-------|--------------|
| IA/0002   | IA_13_a_Change in test proc. for active substance -                                              | 18/05/2009   | n/a   | minor change |
| IA/0001   | IA_13_a_Change in test proc. for active substance - minor change                                 | 18/05/2009   | n/a   |              |